Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2024 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Krystal Biotech Q4 2024 Earnings Call. At this time, all participants are on a listen-only mode.
Krystal Biotech Inc. (KRYS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 2,628,822 | $411,831,255 | +1% | 5.82% |
| 2. | Redmile Group Jeremy Green | 753,175 | $117,992,396 | -8% | 8.22% |
| 3. | Hood River Capital Management David Swank | 512,726 | $80,323,655 | 1.18% | |
| 4. | Soleus Capital Guy Levy | 358,379 | $56,143,654 | +66% | 3.52% |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 221,102 | $34,637,839 | +23% | 0.23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 25,000 | Large Shareholder, Officer, Director | 2,001,462 | 2018-10-18 | Filing | |
| $20.00 | 25,000 | Large Shareholder, Officer, Director | 2,036,462 | 2018-10-18 | Filing | |
| $12.45 | 1,018 | Large Shareholder, Officer, Director | 1,976,462 | 2018-06-06 | Filing | |
| $11.15 | 13,116 | Large Shareholder, Officer, Director | 1,975,444 | 2018-06-06 | Filing | |
| $10.75 | 10,866 | Large Shareholder, Officer, Director | 1,962,328 | 2018-06-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $179.57 | 1,256 | Large Shareholder, Officer, Director | 1,533,056 | 2025-03-13 | Filing | |
| $178.77 | 6,769 | Large Shareholder, Officer, Director | 1,534,312 | 2025-03-13 | Filing | |
| $177.62 | 10,931 | Large Shareholder, Officer, Director | 1,541,081 | 2025-03-13 | Filing | |
| $176.80 | 4,944 | Large Shareholder, Officer, Director | 1,552,012 | 2025-03-13 | Filing | |
| $175.83 | 1,100 | Large Shareholder, Officer, Director | 1,556,956 | 2025-03-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 68,727 | $12,391,455 | 0.01% | |
| 2. | 10,205 | $1,839,962 | 0.08% | |
| 3. | 9,570 | $1,725,471 | 0.02% | |
| 4. | 8,491 | $1,530,927 | 0.04% | |
| 5. | 3,867 | $654,026 | 0.25% |
News See All
Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by and welcome to Krystal Biotech's Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.
10 Worst Booming Stocks to Buy According to Short Sellers
September has historically been one of the worst months for US stocks.
Krystal Biotech (KRYS) Surged as it Beat the Streat Estimates with Wide Margin
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2024 investor letter.
Is Krystal Biotech, Inc. (NASDAQ:KRYS) the Premier Gene Therapy Stock for Your Portfolio?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Krystal Biotech, Inc.
9 Best Gene Therapy Stocks to Buy Now
In this article, we will be discussing the best gene therapy stocks to buy now. Before we move on to our list, let's take a look at the market outlook for gene therapies and understand the reasons behind...
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2024 Earnings Call Transcript
Krystal Biotech, Inc. misses on earnings expectations. Reported EPS is $0.03182 EPS, expectations were $0.2. Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2023 Earnings Call Transcript
Operator: Thank you for standing by and welcome to the Krystal Biotech Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are on a lesson-only mode.
12 Best Genomics Stocks To Buy Now
In this piece, we will take a look at the 12 best genomics stocks to buy now.
Here’s Why TimesSquare Capital Management U.S. Small Cap Growth Strategy Added Krystal Biotech (KRYS)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here.
Billionaire Hedge Funds
